BWV - Blue Water Vaccines in pact to study Alzheimer's vaccine

• Newly IPO’d biotech Blue Water Vaccines ( NASDAQ: BWV ) announced a sponsored research agreement with Cincinnati Children’s Hospital Medical Center on Wednesday to study vaccine candidate for conditions such as Alzheimer’s. The news sent company shares more than 11% higher in late trading.
• In July 2021, Cincinnati Children’s and Blue Water Vaccines ( BWV ) inked a global licensing agreement to jointly develop vaccines targeted at multiple indications using the Medical Center virus-like particle (VLP) vaccine platform.
• Under the previous agreement, the parties have led studies for BWV-301 in gastroenteritis caused by norovirus or rotavirus.
• With the new partnership, Blue Water Vaccines ( BWV ) has agreed to fund studies to explore the potential of the platform in other conditions such as influenza and Alzheimer’s disease.

For further details see: